Sanofi-Aventis Shuts Down Acomplia TrialsTwo weeks after the European Medicines Agency (EMEA) decided the risks of Sanofi-Aventis’ weight-loss drug Acomplia are greater than the benefits and recommended suspending its marketing authorization, the company decided to discontinue its development.Read More
Pfizer Discontinues Development of Obesity CompoundPfizer is terminating its Phase III development program for its investigational compound CP-945,598 for weight management.Read More
Hepatitis C Drug Fails to Meet Study’s Main GoalSciClone Pharmaceuticals’ Phase III study evaluating thymalfasin did not meet its main objective in treating patients with hepatitis C (HCV).Read More
Tarceva Improves Progression-Free Survival in Lung Cancer TrialTarceva significantly extended the time patients with advanced nonsmall cell lung cancer (NSCLC) lived without their cancer getting worse, according to a joint statement by Genentech and OSI Pharmaceuticals.Read More
Trial for Premature Ejaculation Treatment Meets EndpointSciele Pharma received positive findings from its Phase III trial of PSD502 as a treatment for premature ejaculation.Read More
J&J Reports Rivaroxaban Success From Phase II TrialJohnson & Johnson’s (J&J) Phase II clinical trial of the experimental anticoagulant rivaroxaban yielded encouraging response rates as a treatment for acute coronary syndrome, the company said.Read More
VIA Gets Goods News From Two Phase II StudiesVIA Pharmaceuticals saw positive results from two Phase II trials using VIA-2291 to treat cardiovascular disease.Read More
Drug Shows Promise in Treating Heart FailureCytokinetics received favorable outcomes from its Phase IIa trial of CK-1827452 in stable heart failure patients. Read More
EyeGate Begins Enrolling Patients in Study for Dry EyeEyeGate Pharma has enrolled its first patient in a Phase II clinical trial of EGP-437 for treating mild-to-moderate dry eye.Read More
Molecular Insight Sees Positive Results from Imaging Agent StudyMolecular Insight Pharmaceuticals received data from its Phase IIb trial that suggests adding Zemiva with quantitative single photon emission computed tomography imaging may help identify chest pain in patients at high risk for acute coronary syndrome (ACS).Read More
|
Shopping Cart
Your shopping cart is empty
|